Infliximab in the Treatment of Severe Psoriasis Vulgaris
Asian Journal of Research in Dermatological Science,
Psoriasis is a chronic, immune mediated inflammatory disease. The inflammatory activity of the psoriasis plaques is partially triggered by activation of the Th1 lymphocytes, which release pro-inflammatory chemokines and cytokines such as tumor necrosis factor alpha (TNF-α). Infliximab is a mouse-human chimeric monoclonal anti body that neutralize the biologic activity of TNF-α by binding to soluble and transmembrance forms of this cytokine and inhibiting it’s binding to the receptors. We aim to assess the efficacy and tolerability of infliximab in severe psoriasis vulgaris.
Materials and Methods: Twenty patients were included in the study, 12 men and 8 women with severe psoriasis vulgaris, were assigned infliximab infusion 5 mg/kg at weeks 0, 2 and 6, followed by maintenance therapy every 8 weeks. For every patient psoriasis activities and treatment efficacy were assessed by measuring Psoriasis Area Severity Index (PASI) scores
Results: Among the 20 patients enrolled in this study, 2 patients are dropped out from the study after first dose due to hypotension or mild urticarial reactions. Eighteen patients had completed the course of treatment for 32 weeks. Maximum PASI score at baseline was 64 and minimum PASI score was 14 (Mean PASI score was 32.88 ±10.871). PASI score was greatly reduced from 32.8 to 16.2 in 6 weeks and to 2.2 in 10 weeks time. 50% improvement at the after the 1st dose (2 weeks) in 8 patients (45.5). In 10 patients (54.5%), 75% improvement in PASI score from baseline at tenth week. About 90% improvement in PASI score in most of our patients (16) at sixteenth week and all patients had complete clearance at twenty 24th week and 32 weeks of treatment. The acute adverse effect was infusion reactions were reported in one patient during the initial 1ST week, and hypotension which occurred at week 2 this lead to discontinuation of the drug. Infections manifested as delayed adverse effects where 2 of 18 patients (11.1%) developed UTI at week 2nd and week 16th also another patient at week 6 developed URTI & UTI from week 0. All reported infections were mild and treated during the course. In conclusion, infliximab was found to be safe and effective and well tolerated in the treatment of recalcitrant plaque psoriasis. To the best of our knowledge this is the first study to be published in Libya and North Africa.
- Psoriasis vulgaris
How to Cite
Joel M. Gelfand, Rachel Weinstein, Steven B. Porter. Prevalence and treatment of Psoriasis in the Kingdom .Arch. Dermatol. 2005:141(12):1537-1541.
Burd RM. Psoriasis: a general overview. Br J Hosp Med. 2006;67:259–62.
Lebowohl M. Psoriasis. Lancet. 2003;361:1197–204.
Lebowohl M, Callen JP. Obesity, smoking and psoriasis. JAMA. 2006;295:208–10
Leman AJ, Burden AD. Treatment of severe psoriasis with infliximab. Ther Clin Risk Mana. 2008;4(6):1165-1176.
Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal anti-body cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251.
Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumor necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146-51.
Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNF- α) . monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829-30.
Thaçi D, A Blauvelt, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. Journal of the Am Acad Dermatol. 2015;73(3):400-409.
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373:1318-1328.
Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials, Ann Rheum Dis. 2005;64(Suppl II):ii65– ii68.
Chow C, Simpson MJ, Luger TTA, Chubb, Ellis CN Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician’s Global Assessment and Lattice System Physician’s Global Assessment. JEADV. 2015;29:1406–1414.
Chaudhari U, Romano P, Mulcahy LD et al, Efficacy and safety of infliximab for plaque type psoriasis: A randomized trial. 2001;357:1842-47.
Amital H, Ingber A, Rubinow A. Infliximab-Induced Remission of Extensive Plaque Psoriasis. IMA J. 2003;5:827-828.
Subedi S, Gong Yu, Chen Y et.al Infliimxab and biosimilar infliximab in psoriasis: Efficacy, loss of efficacy, and adverse events . Drug Design, Development and Therapy. 2019;13:2491–2502.
Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-74.
Gottlieb AB, Chaudhari U, Mulcahy L, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasism Am Acad Dermatol. 2003;48(60):829-35.
Kim WB, Marinas JE, Qiang J, Shahbaz A, Greaves S, Yeung J. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: a Canadian multicenter retrospective study. J Am Acad Dermatol. 2015;73(2):237–241.
Kleyn CE, Griffiths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther. 2006;6(8):797–805.
Kipnis D, Wendy A, Opeola M et al. Biologic treatments for psoriasis. J Am Acad Dermatol 2005;52:671-82.
Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the worid. J Eur Acad Dermatol Venereol. 2001;15:16-7.
Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23-6.
Duarte AA, Chehin FB. Moderate to severe psoriasis treated with infliximab- 53 patients profile, efficacy and adverse effects. An Bras Dermatol. 2011;86:257-63.
Lecluse LL, Piskin G, Mekkes JR, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159:527- 36.
Abstract View: 25 times
PDF Download: 7 times